Hofseth BioCare Croissance future

Future contrôle des critères 0/6

Nous ne disposons actuellement pas d'une couverture d'analyste suffisante pour prévoir la croissance et les revenus de Hofseth BioCare.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Biotechs croissance des bénéfices	10.4%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Recent updates

Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain

Nov 20

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme Hofseth BioCare n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

OB:HBC - Estimations futures des analystes et données financières antérieures (NOK Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
9/30/2024	248	-133	-61	-59	N/A
6/30/2024	230	-121	-29	-19	N/A
3/31/2024	226	-98	-28	-17	N/A
12/31/2023	219	-107	-11	3	N/A
9/30/2023	205	-93	46	64	N/A
6/30/2023	185	-105	-6	11	N/A
3/31/2023	134	-140	-54	-36	N/A
12/31/2022	120	-137	-63	-45	N/A
9/30/2022	113	-136	-133	-114	N/A
6/30/2022	96	-139	-110	-90	N/A
3/31/2022	102	-135	-84	-53	N/A
12/31/2021	88	-126	-100	-62	N/A
9/30/2021	85	-120	-103	-59	N/A
6/30/2021	79	-115	-100	-43	N/A
3/31/2021	68	-111	-114	-56	N/A
12/31/2020	69	-102	-116	-62	N/A
9/30/2020	57	-104	-103	-54	N/A
6/30/2020	79	-90	-99	-63	N/A
3/31/2020	72	-86	-73	-49	N/A
12/31/2019	68	-89	-51	-31	N/A
9/30/2019	71	-79	19	25	N/A
6/30/2019	59	-81	-36	-36	N/A
3/31/2019	61	-83	-31	-23	N/A
12/31/2018	61	-85	-38	-29	N/A
9/30/2018	73	-74	-104	-81	N/A
6/30/2018	84	-66	N/A	-3	N/A
3/31/2018	75	-66	N/A	-20	N/A
12/31/2017	66	-16	N/A	-25	N/A
9/30/2017	43	-28	N/A	-18	N/A
6/30/2017	19	-60	N/A	-43	N/A
3/31/2017	21	-92	N/A	-70	N/A
12/31/2016	20	-147	N/A	-67	N/A
9/30/2016	21	-165	N/A	-8	N/A
6/30/2016	34	-137	N/A	-2	N/A
3/31/2016	32	-109	N/A	1	N/A
12/31/2015	32	-100	N/A	8	N/A
9/30/2015	38	-84	N/A	-54	N/A
6/30/2015	23	-82	N/A	-47	N/A
3/31/2015	24	-72	N/A	-72	N/A
12/31/2014	20	-67	N/A	-61	N/A
9/30/2014	39	-40	N/A	-70	N/A
6/30/2014	62	-35	N/A	-103	N/A
3/31/2014	63	-39	N/A	-58	N/A
12/31/2013	63	-52	N/A	-77	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de HBC est supérieure au taux d'épargne ( 2.4% ).

Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de HBC devraient croître plus rapidement que le marché Norwegian

Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de HBC devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de HBC devraient croître plus rapidement que le marché Norwegian.

Croissance élevée des revenus: Données insuffisantes pour déterminer si les revenus de HBC devraient croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de HBC devrait être élevé dans 3 ans

Hofseth BioCare Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Hofseth BioCare ASA Provides Earnings Guidance for the Second Half of 2021 and Next Year 2022

Recent updates

Hofseth BioCare ASA, Annual General Meeting, May 23, 2025

Third quarter 2024 earnings released: kr0.09 loss per share (vs kr0.057 loss in 3Q 2023)

Hofseth BioCare ASA to Report Q4, 2025 Results on Feb 13, 2026

Hofseth BioCare ASA to Report First Half, 2025 Results on Aug 22, 2025

Hofseth Biocare Asa Announces Resignation of Christel Elise Kanli as CFO

Hofseth Biocare Asa Announces Resignation of Christel Elise Kanli as CFO

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: kr0.04 loss per share (vs kr0.015 profit in 2Q 2023)

Less than half of directors are independent

First quarter 2024 earnings released: kr0.07 loss per share (vs kr0.096 loss in 1Q 2023)

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022)

New minor risk - Share price stability

Hofseth BioCare ASA Announces Board Changes

New major risk - Financial position

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022)

Hofseth BioCare ASA to Report Q4, 2024 Results on Feb 14, 2025

Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.09 loss in 3Q 2022)

New minor risk - Market cap size

Second quarter 2023 earnings released: EPS: kr0.015 (vs kr0.079 loss in 2Q 2022)

CFO & COO recently bought kr200k worth of stock

New minor risk - Market cap size

Hofseth Biocare ASA Announces the Online Publication of Its Abstract

First quarter 2023 earnings released: kr0.10 loss per share (vs kr0.10 loss in 1Q 2022)

Here's Why Hofseth BioCare (OB:HBC) Can Afford Some Debt

Chief Scientific Officer recently bought kr538k worth of stock

Independent Director recently bought kr272k worth of stock

Full year 2022 earnings released: kr0.37 loss per share (vs kr0.35 loss in FY 2021)

We Think Hofseth BioCare (OB:HBC) Has A Fair Chunk Of Debt

Hofseth BioCare ASA to Report Fiscal Year 2022 Results on Mar 31, 2023

Third quarter 2022 earnings released: kr0.09 loss per share (vs kr0.11 loss in 3Q 2021)

Third quarter 2022 earnings released: kr0.09 loss per share (vs kr0.11 loss in 3Q 2021)

Hofseth BioCare ASA's Progo Bioactive Peptides Now Is A "New Dietary Ingredient" for the US FDA

Second quarter 2022 earnings released: kr0.08 loss per share (vs kr0.069 loss in 2Q 2021)

Hofseth BioCare ASA Announces Executive Changes

Chief Executive Officer recently bought kr170k worth of stock

First quarter 2022 earnings released: kr0.10 loss per share (vs kr0.075 loss in 1Q 2021)

Health Check: How Prudently Does Hofseth BioCare (OB:HBC) Use Debt?

Full year 2021 earnings released: kr0.35 loss per share (vs kr0.31 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Chief Executive Officer recently bought kr367k worth of stock

Hofseth Biocare ASA Successfully Receive New Dietary Ingredient (NDI) Status from the US FDA

Third quarter 2021 earnings released: kr0.11 loss per share (vs kr0.10 loss in 3Q 2020)

Hofseth BioCare (OB:HBC) Is Carrying A Fair Bit Of Debt

Chief Commercial Officer recently bought kr200k worth of stock

Chief Executive Officer recently bought kr361k worth of stock

Second quarter 2021 earnings released: kr0.07 loss per share (vs kr0.062 loss in 2Q 2020)

Hofseth BioCare ASA Provides Earnings Guidance for the Second Half of 2021 and Next Year 2022

Independent Director recently bought kr385k worth of stock

First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.055 loss in 1Q 2020)

Full year 2020 earnings released: kr0.31 loss per share (vs kr0.29 loss in FY 2019)

Is Hofseth BioCare (OB:HBC) Using Debt Sensibly?

Full year 2020 earnings released: kr0.31 loss per share (vs kr0.29 loss in FY 2019)

How Much Of Hofseth BioCare ASA (OB:HBC) Do Insiders Own?

Chief Executive Officer recently bought kr505k worth of stock

Chief Executive Officer recently bought kr505k worth of stock

Chief Executive Officer recently bought kr505k worth of stock

New 90-day high: kr9.80

Are Insiders Buying Hofseth BioCare ASA (OB:HBC) Stock?

Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 39.999995 million.

Hofseth Biocare ASA and Tenet Partners Initiate A Long-Term Collaboration to Build A Global Brand and Launch HBC Own Branded Consumer Health Products

Hofseth BioCare ASA and DKSH Announces A Pan-Asian Exclusive Collaboration for Distribution of HBC Branded Products Including Across China, India, Japan & Korea

Hofseth Biocare Asa Signs Exclusive Distribution Agreement with Leading Speciality Chemicals and Ingredients Distributor IMCD

Hofseth Biocare ASA Hires Andy Gill as VP from January 2021

Hofseth BioCare ASA, Annual General Meeting, Apr 23, 2021

Hofseth BioCare (OB:HBC) Shareholders Have Enjoyed A Whopping 339% Share Price Gain

Hofseth Biocare ASA Approves Appointment of Christoph Baldegger as New Member of the Audit Committee

Third quarter earnings released

New 90-day low: kr7.98

HBC Receives Approval from Health Canada for Qualified Health Claims Focused on Maintaining Healthy Levels of Ferritin and Hemoglobin and the Blood Components Required for Oxygen Transport

Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 200 million.

Hofseth Biocare ASA's Progo’s Bioactive Peptides to Support Healthy Iron Levels to Be Launched in the US

Hofseth BioCare ASA Announces the First Part of its Accelerated Phase 2 Trial of Cardio™ Soft Gels for the Treatment of Patients with COVID-19

New 90-day low - kr8.16

First half earnings released